Phenobarbital and its Sodium Salt - IARC Monographs on the ...
Phenobarbital and its Sodium Salt - IARC Monographs on the ...
Phenobarbital and its Sodium Salt - IARC Monographs on the ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table 2 (c<strong>on</strong>td)<br />
Country (reference) Subjects Exposure estimates Odds ratio (95% CI) Comments<br />
Childhood neuroblastoma<br />
USA<br />
(Kramer et al., 1987)<br />
Lung cancer<br />
Denmark<br />
(Olsen et al., 1993)<br />
Bladder cancer<br />
Denmark<br />
(Olsen et al., 1993)<br />
Primary liver cancer<br />
Denmark<br />
(Olsen et al., 1995)<br />
104 patients<br />
104 c<strong>on</strong>trols<br />
104 patients<br />
200 c<strong>on</strong>trols<br />
18 patients<br />
33 c<strong>on</strong>trols<br />
26 patients<br />
49 c<strong>on</strong>trols<br />
Mo<strong>the</strong>rs’ phenobarbital<br />
use<br />
Neurally active drugs<br />
<str<strong>on</strong>g>Phenobarbital</str<strong>on</strong>g> treatment<br />
Ever versus never<br />
1–749 g<br />
≥ 750 g<br />
<str<strong>on</strong>g>Phenobarbital</str<strong>on</strong>g> treatment<br />
Ever versus never<br />
1–749 g<br />
≥ 750 g<br />
<str<strong>on</strong>g>Phenobarbital</str<strong>on</strong>g> treatment<br />
Ever versus never<br />
5–749 g<br />
≥ 750 g<br />
[2.9%]<br />
[0.0%]<br />
2.8 (1.3–6.0)<br />
1.2<br />
1.6<br />
1.0<br />
0.3<br />
0.6<br />
0.2<br />
2.0<br />
0.4<br />
3.2<br />
(0.7–2.2)<br />
(0.8–3.0)<br />
(0.5–1.8)<br />
(0.1–0.9)<br />
(0.1–2.7)<br />
(0.0–0.9)<br />
(0.5–7.2)<br />
(0.1–3.4)<br />
(0.7–14)<br />
Formal risk estimates<br />
were not provided.<br />
90% CI<br />
176<br />
<str<strong>on</strong>g>IARC</str<strong>on</strong>g> MONOGRAPHS VOLUME 79